-
Mashup Score: 12Blood-based colorectal cancer screening in an integrated health system: a randomised trial of patient adherence - 15 day(s) ago
Objective We evaluated whether people who had not completed a faecal immunochemical test (FIT) for colorectal cancer (CRC) screening would complete a blood-based testing option if offered one during health encounters. Blood-based screening tests for CRC could add to the total number of people screened for CRC by providing another testing alternative. Design Study participants were patients aged 45–75 years at a large, integrated health system who were offered but did not complete an FIT in the prior 3–9 months and were scheduled for a clinical encounter. Individuals were randomised (1:1) to be offered a commercially available CRC blood test (Shield, Guardant Health) versus usual care. We compared 3-month CRC screening proportions in the two groups. Results We randomised 2026 patients; 2004 remained eligible following postrandomisation exclusions (1003 to usual care and 1001 to blood draw offer; mean age: 60, 62% female, 80% non-Hispanic white). Of the 1001 allocated to the blood test g
Source: gut.bmj.comCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 4Neoadjuvant botensilimab plus balstilimab response pattern in locally advanced mismatch repair proficient colorectal cancer - 2 month(s) ago
Oncogene – Neoadjuvant botensilimab plus balstilimab response pattern in locally advanced mismatch repair proficient colorectal cancer
Source: www.nature.comCategories: General Medicine News, Oncologists2Tweet
-
Mashup Score: 6Mutational Signature Changes in Patients With Metastatic Squamous Cell Carcinoma of the Anal Canal - 3 month(s) ago
This study aimed to describe how tissue-based and ctDNA-based mutational concordance, as identified by next-generation sequencing, is affected by chemoradiation
Source: academic.oup.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 133
Nature Medicine – In an arm of a phase 1b trial, the combination of divarasib, a KRAS G12C inhibitor, and cetuximab, an epidermal growth factor receptor inhibitor, was well tolerated with an…
Source: www.nature.comCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 126
Nature Medicine – In an arm of a phase 1b trial, the combination of divarasib, a KRAS G12C inhibitor, and cetuximab, an epidermal growth factor receptor inhibitor, was well tolerated with an…
Source: www.nature.comCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 126
Nature Medicine – In an arm of a phase 1b trial, the combination of divarasib, a KRAS G12C inhibitor, and cetuximab, an epidermal growth factor receptor inhibitor, was well tolerated with an…
Source: www.nature.comCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 87Pan-Cancer Prevalence of Microsatellite Instability-High (MSI-H) Identified by Circulating Tumor DNA and Associated Real-World Clinical Outcomes - 5 month(s) ago
MSI-H identified by ctDNA: prevalence across 21 advanced cancers and outcomes from >700 patients.
Source: ascopubs.orgCategories: General Medicine News, Hem/OncsTweet-
🗞️Just published @JCOPO_ASCO At the intersection of Liquid Biopsies🔄Precision Medicine Pan-cancer assessment of ✅PLASMA🩸MSI-High and assessment of real-world outcomes. 👉🏾1.4% of 171,881 patients. 💡If shed, 🧬#ctDNA MSI reliable. @OncoAlert @ASCO https://t.co/qoWKZaqEsH https://t.co/J3eZvJvO27 https://t.co/fT90MkoREM
-
-
Mashup Score: 1The emerging role of ctDNA in breast cancer - 5 month(s) ago
Liquid biopsies hold great promise in precision medicine in breast cancer
Source: dailyreporter.esmo.orgCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 9ctDNA response after pembrolizumab in non-small cell lung cancer: phase 2 adaptive trial results - 6 month(s) ago
Nature Medicine – In the first stage of the BR.36 adaptive trial in patients with non-small cell lung cancer receiving anti-PD1 immunnotherapy, the primary endpoint of concordance between…
Source: www.nature.comCategories: Hem/Oncs, Latest HeadlinesTweet
-
Mashup Score: 5Circulating Tumor DNA Identified in Breast Milk From Women With Breast Cancer: First Results Published - The ASCO Post - 6 month(s) ago
Breast milk from women with breast cancer who were diagnosed during pregnancy or postpartum contains circulating tumor DNA (ctDNA), according to researchers at the Vall d’Hebron Institute of Oncology (VHIO) in Barcelona. The investigators noted that ctDNA can be detected through liquid biopsy in breast milk and may prove to be a new tool for early diagnosis of breast cancer in the postpartum period. The study was led by Cristina Sa ura, MD, and Ana Vivancos, MD, both of VHIO, and the first results were
Source: ascopost.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
The value of a #ctDNA🩸liquid biopsy is underestimated. As an oncologist, I see patients with metastatic cancers everyday who never got screened. 👇🏾See this randomized trial. Just a phone call @aboutKP to offer the🩸to who didn’t do FIT💩. @OncoAlert https://t.co/3p6xO4XnOu https://t.co/MLeg9pFVLI